Literature DB >> 25366143

Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.

Lin Qi1, Yang Zhang.   

Abstract

Aurora-A kinases are overexpressed in many cancer tissues and cells. Alisertib is an investigational, orally administered, selective, small-molecule Aurora-A kinase inhibitor with preclinical activity against a broad range of tumors. Our study was aimed to detect the effects of alisertib on human tongue squamous cell carcinoma (HTSCC). Treatment of a human tongue squamous cell carcinoma cell line, HSC-3, with alisertib to inhibition of Aurora-A kinases reduced proliferation and induced apoptosis, which was accompanied by activation of the ATM/Chk2/p53 pathway. In vivo, inhibition of Aurora-A kinases in established xenografted tumors decreased tumor size and weight. Kaplan-Meyer survival analysis demonstrated that the cumulative survival time of mice without Aurora-A kinases was significantly longer than those with Aurora-A kinases. Our data provide the basis for developing alisertib to treat human tongue squamous cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25366143     DOI： 10.1007/s13277-014-2782-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  25 in total

Review 1.  Mitotic kinases as regulators of cell division and its checkpoints.

Authors:  E A Nigg
Journal:  Nat Rev Mol Cell Biol       Date:  2001-01       Impact factor: 94.444

2.  p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2.

Authors:  J Karlseder; D Broccoli; Y Dai; S Hardy; T de Lange
Journal:  Science       Date:  1999-02-26       Impact factor: 47.728

3.  Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Arijit Chakravarty; Lee Silverman; Mengkun Zhang; Kara M Hoar; Stephen G Stroud; Wei Chen; Vaishali Shinde; Jessica J Huck; Deborah R Wysong; David A Janowick; Marc L Hyer; Patrick J Leroy; Rachel E Gershman; Matthew D Silva; Melissa S Germanos; Joseph B Bolen; Christopher F Claiborne; Todd B Sells
Journal:  Clin Cancer Res       Date:  2011-10-20       Impact factor: 12.531

4.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Authors:  Güllü Görgün; Elisabetta Calabrese; Teru Hideshima; Jeffrey Ecsedy; Giulia Perrone; Mala Mani; Hiroshi Ikeda; Giada Bianchi; Yiguo Hu; Diana Cirstea; Loredana Santo; Yu-Tzu Tai; Sabikun Nahar; Mei Zheng; Madhavi Bandi; Ruben D Carrasco; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

5.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Authors:  Andrew A Mortlock; Kevin M Foote; Nicola M Heron; Frédéric H Jung; Georges Pasquet; Jean-Jacques M Lohmann; Nicolas Warin; Fabrice Renaud; Chris De Savi; Nicola J Roberts; Trevor Johnson; Cyril B Dousson; George B Hill; David Perkins; Glenn Hatter; Robert W Wilkinson; Stephen R Wedge; Simon P Heaton; Rajesh Odedra; Nicholas J Keen; Claire Crafter; Elaine Brown; Katherine Thompson; Stephen Brightwell; Liz Khatri; Madeleine C Brady; Sarah Kearney; David McKillop; Steve Rhead; Tony Parry; Stephen Green
Journal:  J Med Chem       Date:  2007-03-21       Impact factor: 7.446

6.  Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Authors:  Arijit Chakravarty; Vaishali Shinde; Josep Tabernero; Andres Cervantes; Roger B Cohen; E Claire Dees; Howard Burris; Jeffrey R Infante; Teresa Macarulla; Elena Elez; Jordi Andreu; Edith Rodriguez-Braun; Susana Rosello; Margaret von Mehren; Neal J Meropol; Corey J Langer; Bert ONeil; Douglas Bowman; Mengkun Zhang; Hadi Danaee; Laura Faron-Yowe; Gary Gray; Hua Liu; Jodi Pappas; Lee Silverman; Chris Simpson; Bradley Stringer; Stephen Tirrell; Ole Petter Veiby; Karthik Venkatakrishnan; Katherine Galvin; Mark Manfredi; Jeffrey A Ecsedy
Journal:  Cancer Res       Date:  2010-12-10       Impact factor: 12.701

7.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Authors:  Kevin R Kelly; Steffan T Nawrocki; Claudia M Espitia; Mengkun Zhang; Johnny J Yang; Swaminathan Padmanabhan; Jeffrey Ecsedy; Francis J Giles; Jennifer S Carew
Journal:  Int J Cancer       Date:  2012-06-28       Impact factor: 7.396

8.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

9.  Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion.

Authors:  Wei Wang; Ning Zhang; Jian Wang; Xian-Min Bu; Cheng-Hai Zhao
Journal:  Asian Pac J Cancer Prev       Date:  2011

10.  Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism.

Authors:  Ling-Ling Liu; Zi-Jie Long; Le-Xun Wang; Fei-Meng Zheng; Zhi-Gang Fang; Min Yan; Dong-Fan Xu; Jia-Jie Chen; Shao-Wu Wang; Dong-Jun Lin; Quentin Liu
Journal:  Mol Cancer Res       Date:  2013-09-05       Impact factor: 5.852
View more
  2 in total

1.  Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.

Authors:  Mari Kogiso; Lin Qi; Frank K Braun; Sarah G Injac; Linna Zhang; Yuchen Du; Huiyuan Zhang; Frank Y Lin; Sibo Zhao; Holly Lindsay; Jack M Su; Patricia A Baxter; Adekunle M Adesina; Debra Liao; Mark G Qian; Stacey Berg; Jodi A Muscal; Xiao-Nan Li
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

Review 2.  The Aurora kinase inhibitors in cancer research and therapy.

Authors:  Jonas Cicenas
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-01       Impact factor: 4.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.